title: 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.
abstract: The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000556:secondary; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D005260:Female; D017325:Hepatitis B Vaccines; D006801:Humans; D008099:Liver / Q000473:pathology / Q000601:surgery; D008113:Liver Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D016031:Liver Transplantation; D008875:Middle Aged; D009367:Neoplasm Staging; D056910:Republic of Korea / Q000453:epidemiology; D014611:Vaccination
chemical_list: D000970:Antineoplastic Agents; D017325:Hepatitis B Vaccines
keywords: Carcinoma; Guidelines; Management; hepatocellular